Repurposing Drugs for Global Diseases

Reduced Cost, Diminished Risk, More Opportunity

At Algernon Pharmaceuticals, our capital-efficient drug development and repurposing strategy allows us to advance research programs in our pipeline at a much lower cost and risk than other new chemical entity research programs. Our lead candidate, NP-251 (Repirinast) has not only gone through its pre-clinical phase, but since it is a previously approved drug, it has a significant safety history in the patient population it was developed to treat. While AP-188 (N,N-Dimethyltryptamine, or DMT) has never been approved, there have been several Phase 1 studies conducted confirming its safety as well, including our own Phase 1 study completed Q1, 2024.

Our Pipeline Programs

Candidate / Indication

Development Stages

Pre-Clinical

Phase 1

Phase 2

Phase 3

Regulatory Review

Inflammatory Disease

Repirinast

Chronic Kidney Disease

Began cGMP Manufacturing - Q1, 2022
Phase 1 Planned – Q2, 2026

Cerebrovascular Disorders

DMT (AP-188)

N, N-DIMETHYLTRYPTAMINE

Stroke / Traumatic Brain Injury (TBI)

Completed Phase 1 Stroke Study – Q1, 2024
Phase 2 Stroke Study Planned – Q3, 2025

Ifenprodil - For Chronic Cough and IPF

Algernon is pleased to announce that on March 27, 2024, it closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 Ifenprodil research program to treat chronic cough and idiopathic pulmonary fibrosis, for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx. For more information on the acquisition agreement Click Here

An Asthma Drug for Chronic Kidney Disease

NP-251 (Repirinast) was originally an asthma drug developed by Mitsubishi Pharma for the Japanese market and we are investigating its potential to reduce kidney fibrosis and inflammation.

LEARN MORE

A Naturally Occurring Drug for Brain Injury Recovery

AP-188 (DMT) is a naturally occurring hallucinogenic compound that has been shown to promote neuroplasticity in-vitro, and to reduce the infarct volume and assist in motor function recovery in a rat stroke occlusion study. We are investigating DMT as a potential treatment for stroke and traumatic brain injury (TBI) patients, through our subsidiary Algernon NeuroScience.

Learn More